Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung

Nanomedicine

Volumn 9, Issue 12, 2014, Pages 1857-1868

  Rynda Apple, Agnieszka ^a   Patterson, Dustin P ^b   Douglas, Trevor ^c  

^a MONTANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT TYLER   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Antigens; Biomaterials; IBALT; Immunology; Influenza; Protein engineering; Vaccine; Virus like particles

Indexed keywords

INFLUENZA VACCINE; VIRUS LIKE PARTICLE VACCINE; ANTIGEN; NANOMATERIAL;

ADAPTIVE IMMUNITY; BACTERIAL PNEUMONIA; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; LUNG; LUNG FUNCTION; LUNG STRUCTURE; LYMPHOID TISSUE; NONHUMAN; PROTEIN ENGINEERING; PROTEIN INDUCTION; PROTEIN STRUCTURE; REVIEW; VACCINATION; VIRUS IMMUNITY; ANIMAL; ANTIGEN PRESENTATION; CYTOLOGY; DENDRITIC CELL; HUMAN; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY; MOUSE; MUCOSAL IMMUNITY; NANOMEDICINE; PNEUMONIA, BACTERIAL; PROCEDURES;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; DENDRITIC CELLS; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNIZATION; INFLUENZA VACCINES; LUNG; LYMPHOID TISSUE; MICE; NANOMEDICINE; NANOSTRUCTURES; PNEUMONIA, BACTERIAL; PROTEIN ENGINEERING; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84908222518     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/NNM.14.107     Document Type: Review

References (69)

1. Smith DM, Simon JK, Baker JR. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13(8), 592-605 (2013).
2. Grgacic EVL, Anderson DA. Virus-like particles: passport to immune recognition. Methods 40(1), 60-65 (2006).
3. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wires Nanomed. Nanobi. 3(2), 174-196 (2011).
4. Schneider-Ohrum K, Ross TM. Virus-like particles for antigen delivery at mucosal surfaces. Curr. Top. Microbiol. 354, 53-73 (2012).
5. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med. 163(4), 487-494 (2003).
6. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 23(10), 523-529 (2005).
7. Roldao A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM. Virus-like particles in vaccine development. Expert Rev. Vaccines 9(10), 1149-1176 (2010).
8. Uchida M, Klem MT, Allen M et al. Biological containers: protein cages as multifunctional nanoplatforms. Adv. Mater. 19(8), 1025-1042 (2007).
9. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006).
10. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 38(1), 114-126 (2008).
11. Bessa J, Zabel F, Link A et al. Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proc. Natl Acad. Sci. USA 109(50), 20566-20571 (2012).
12. Ichinohe T, Pang IK, Kumamoto Y et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl Acad. Sci. USA 108(13), 5354-5359 (2011).
13. Pabst R. Is BALT a major component of the human lung immune system? Immunol Today 13(4), 119-122 (1992).
14. Pabst R, Gehrke I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Am. J. Respir. Cell Mol. Biol. 3(2), 131-135 (1990).
15. Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 68(1), 1-8 (2000).
16. Randall TD. Bronchus-associated lymphoid tissue (BALT) structure and function. Adv. Immunol. 107, 187-241 (2010).
17. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10(9), 927-934 (2004).
18. Wiley JA, Richert LE, Swain SD et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One 4(9), e7142 (2009).
19. + T cell responses. Lymphat. Res. Biol. 11(4), 196-202 (2013).
20. Jupelli M, Shimada K, Chiba N et al. Chlamydia pneumoniae infection in mice induces chronic lung inflammation, iBALT formation, and fibrosis. PLoS One 8(10), e77447 (2013).
21. Richert LE, Servid AE, Harmsen AL et al. A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 30(24), 3653-3665 (2012).
22. Richert LE, Rynda-Apple A, Harmsen AL et al. CD11c+ cells primed with unrelated antigen facilitate an accelerated immune responses to influneza virus in mice. Eur. J. Immunol. 44, 397-408 (2013).
23. Zabel F, Kundig TM, Bachmann MF. Virus-induced humoral immunity: on how B cell responses are initiated. Curr. Opin Virol. 3(3), 357-362 (2013).
24. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404-1413 (2008).
25. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J. Immunol. 188(8), 3724-3733 (2012).
26. Lechner F, Jegerlehner A, Tissot AC et al. Virus-like particles as a modular system for novel vaccines. Intervirology 45(4-6), 212-217 (2002).
27. Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J. Virol. 79(2), 717-724 (2005).
28. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15, 235-270 (1997).
29. Bachmann MF, Kopf M. The role of B cells in acute and chronic infections. Curr. Opin Immunol. 11(3), 332-339 (1999).
30. Carroll MC. The complement system in regulation of adaptive immunity. Nat. Immunol. 5(10), 981-986 (2004).
31. Carroll MC. The complement system in B cell regulation. Mol. Immunol 41(2-3), 141-146 (2004).
32. Kalbfuss B, Knochlein A, Krober T, Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 36(3), 145-161 (2008).
33. Thompson CM, Petiot E, Lennaertz A, Henry O, Kamen AA. Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virol. J. 10, 141 (2013).
34. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59(1), 1-15 (2004).
35. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 3(6), 643-654 (2004).
36. Sun K, Ye J, Perez DR, Metzger DW. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J. Immunol. 186(2), 987-993 (2011).
37. Kaiser J. A One-size-fits-all flu vaccine? Science 312(5772), 380-382 (2006).
38. Fouchier RA, Munster V, Wallensten A et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79(5), 2814-2822 (2005).
39. Rohm C, Zhou N, Suss J, Mackenzie J, Webster RG. Characterization of a novel influenza hemagglutinin, H15: criteria for determination of influenza A subtypes. Virology 217(2), 508-516 (1996).
40. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56(1), 152-179 (1992).
41. Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 143(2), 140-146 (2009).
42. Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19), 3871-3878 (2007).
43. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81(7), 3514-3524 (2007).
44. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18(1), 244-251 (2005).
45. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82(3), 1350-1359 (2008).
46. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75(11), 5141-5150 (2001).
47. Skountzou I, Quan FS, Gangadhara S et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J. Virol. 81(3), 1083-1094 (2007).
48. Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 82(23), 11813-11823 (2008).
49. D'aoust MA, Lavoie PO, Couture MM et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 6(9), 930-940 (2008).
50. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64(3), 1375-1377 (1990).
51. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999).
52. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172(9), 5598-5605 (2004).
53. Denis J, Acosta-Ramirez E, Zhao Y et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26(27-28), 3395-3403 (2008).
54. Denis J, Acosta-Ramirez E, Savard C et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 363(1), 59-68 (2007).
55. Savard C, Guérin A, Drouin K et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS ONE (6(6), e21522 (2011).
56. Patterson DP, Rynda-Apple A, Harmsen AL, Harmsen AG, Douglas T. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 7(4), 3036-3044 (2013).
57. Schneemann A, Speir JA, Tan GS et al. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J. Virol. 86(21), 11686-11697 (2012).
58. Kanekiyo M, Wei CJ, Yassine HM et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499(7456), 102-106 (2013).
59. Greene CM, Mcelvaney NG. Toll-like receptor expression and function in airway epithelial cells. Arch. Immunol. Ther. Exp. (Warsz) 53(5), 418-427 (2005).
60. Akira S, Yamamoto M, Takeda K. Role of adapters in Toll-like receptor signalling. Biochem. Soc. Trans. 31(Pt 3), 637-642 (2003).
61. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
62. Van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans. 36(Pt 6), 1478-1481 (2008).
63. Canton J, Neculai D, Grinstein S. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 13(9), 621-634 (2013).
64. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227(1), 221-233 (2009).
65. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 327(5963), 291-295 (2010).
66. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10(12), 826-837 (2010).
67. Keller SA, Bauer M, Manolova V, Muntwiler S, Saudan P, Bachmann MF. Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J. Immunol. 184(1), 26-29 (2010).
68. Rynda-Apple A, Dobrinen E, Mcalpine M et al. Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function. Am. J. Pathol. 181(1), 196-210 (2012).
69. Mathieu C, Rioux G, Dumas MC, Leclerc D. Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge. Nanomedicine 9(7), 839-848 (2013).